RADIENT PHARMACEUTICALS Corp

RADIENT PHARMACEUTICALS — Investor Presentation (April 2011)

16 slides from RADIENT PHARMACEUTICALS's investor presentation, Apr 29, 2011

  1. Slide 1: Investor Presentation Q2 2011

    RAIQNL concer ring notin oierenc PHARMACEUTICALS Investor Presentation Q2 2011 Ticker Symbol NYSE Amex: “RPC” Recent Share Price $0.40 52-Week High $4.75 52-Week Low $0.28 ‘Average Volume 4,223,180 Shares Outstanding 118M Market Capitalization | $47.2M Mr. Douglas Mactellan Ms. Kristine Szarkowitz C

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward- looking statements under securities law. These statements involve a number of

  3. Slide 3: Company Overview

    Company Overview + RPC develops, manufactures and distributes novel IVD cancer products + Addressing significant unmet healthcare need with *$10.1B market opportunity in 2014 + Lead Product — Onko-Sure® — Clinically proven, US FDA-cleared IVD test that detects and/or monitors more than 19 different

  4. Slide 4: Market Opportunity

    Market Opportunity 5-year Projected Worldwide Oncology IVD Product Sales (in Sbillions) “7 $10.18 > 2009 2010 2011 2012 2013 2014 ‘Source: Kalorema information Radient PHARMACEUTICALS

  5. Slide 5: Onko-Sure IVD Cancer Test

    Onko-Sure® IVD Cancer Test Simple, reliable, non-invasive blood test that measures the accumulation of specific breakdown products in the blood called Fibrin. and Fibrinogen Degradation Products (FDP). Detects and/or monitors 19 types of cancer, including: liver, stomach, tongue, ovarian, pancreatic

  6. Slide 6: Product Commercialization

    Product Commercialization + Market Opportunity: — Worldwide IVD Oncology market growing at a 11% CAGR (Source: Kalorama Information) - Market estimated to reach $10.1 billion by 2014 — Market for cancer tumor markers expected to significantly expand over the next 5 years based on growing incidence o

  7. Slide 7: Clinical Developments — Validation Study

    Clinical Developments — Validation Study * Conducted clinical study for the validation of Onko-Sure” as a useful tool in the detection of all stages of colorectal cancer. + Study is the largest to date for Onko-Sure*: — Approximately 1,000 colorectal patient samples with various disease stages teste

  8. Slide 8: Study Results (N=926)

    Study Results (N=926) > Onko-Sure® IVD cancer test can be up to 17% more effective in detecting CRC in Stages | and II over Carcinoembryonic Antigen (CEA). > When Onko-Sure® is combined with CEA, the combined tests deliver a 20% increased sensitivity as opposed to using CEA alone. Onko-Sure® DR-70 i

  9. Slide 9: Financial & Operational Highlights

    Financial & Operational Highlights + Implemented Successful Debt Recapitalization Plan Pursuant to shareholder approval, converted approximately $24.5M of principal and interest in corporate debt since December 2010 * Private Placement of Convertible Notes & Warrants (Q1 2011) Raised approximately $

  10. Slide 10: Growth Strategy

    Growth Strategy Product Commercialization: aggressive international sales of RPC’s Onko-Sure* IVD Cancer Test Partnerships: Leverage brand & reputation of clinical trial partners to increase brand and product awareness and sales Increased Marketing: Execute additional sales, marketing and PR campaig

  11. Slide 11: Investment Highlights

    al Investment Highlights + High Value, Differentiated IVD Cancer Test: Clinically proven, USFDA-cleared IVD cancer test — Only alternative to CEA blood test — Monitors and/or detects more than 19 different types of cancer ~ Only general cancer screen commercially available — Has potential to reduce

  12. Slide 12: FY2011 Asset Development Plan

    FY2011 Asset Development Plan RPC owns AMDL Diagnostics inc. (developer, manufacturer and distributor of IVD cancer tests); and owns and/or is developing two additional separate cancer-centric businesses. NuVax + Formed in December FY2010 to advance newly in-licensed cancer therapies (initially) for

  13. Slide 13: Douglas MacLellan

    Douglas MacLellan Executive Chairman & CEO Douglas C. Mactellan is Chairman of the Board of Directors and Chief Executive Officer of Radient Pharmaceuticals Corporation — a US-based pharmaceutical company with major operations in China. Through MacLellan’s leadership, Radient Pharmaceuticals is on a

  14. Slide 14: Akio Ariura

    Akio Ariura Chief Operating Officer & CFO Mr. Akio Ariura was named Chief Operating Officer of Radient Pharmaceuticals in 2008 and continues to serve in the role of Chief Financial Officer, ‘a senior role Mr. Ariura has held with the Company since. His experience spans over 30 years in both private

  15. Slide 15: Mr Christopher Gee

    Mr Christopher Gee irector, International Sales & Marketing Mr. Chris Gee is a tech/biotech industry veteran with extensive international sales, marketing, and distribution management experience. Since 2004 he has held executive positions and managed projects in the USA, PRC China, Hong Kong, Vietna

  16. Slide 16: Board of Directors

    Board of Directors Mr. Douglas MacLellan: Chairman & CEO, Radient Pharmaceuticals. See complete bio under “Executive Management Team’ section Dr. Robert Beart Jr.; Independent Director. Dr. Beart Jr. is the medical director of the Glendale Hospital CRC Institute. Previously he had been with the Univ

Radient Pharmaceuticals — Investor Presentation (April 2011) on 6ix